Knowledge Ecology International

August 28, 2011
From KEI staff review of Wikileaks cables (/wikileaks)

Among the many new cables released by Wikileaks is this gem, a detailed account of the U.S. government pressure on the Guatemala legislature to shape legislation on pharmaceutical test data IPR.

http://wikileaks.org/cable/2005/03/05GUATEMALA659.html

C O N F I D E N T I A L SECTION 01 OF 05 GUATEMALA 000659

SIPDIS
E.O. 12958: DECL: 03/11/2010

TAGS: ETRD KIPR PGOV PREL GT

 Continue Reading →
		

Posted August 27, 2011

These are some tools for searching the US Department of State cables released by Wikileaks.

A Wikileaks page on the cables is available here: http://wlcentral.org/cablegate

KEI recommends this site for searching the cables by key words:

http://cablegatesearch.net/search.php

You might also want to try:

• http://cabledrum.net

Continue Reading →

As part of the American University hosted Global Congress on Intellectual Property and the public Interest, I participated in a panel on the positive agenda for intellectual property. These are notes from my talk.

Presentation by Manon Anne Ress, Knowledge Ecology International
August 26, 2011, at American University in Washington, DC

Continue Reading →

AIDS Drug Assistance Programs (ADAP) serve low-income, underinsured or uninsured HIV-positive patients in the United States and its territories. General eligibility requirements may include residency, clinical eligibility based on specific CD4 counts, and income. Specific eligibility criteria for each ADAP is determined by each individual state. Continue Reading →

The number of patients sitting on AIDS Drug Assistance Programs (ADAP) wait lists, denied the life-saving treatment they need, have risen dramatically over the past two years. ADAPs are critical in providing HIV/AIDS treatment to low-income, uninsured, or underinsured patients within the United States and its territories. As noted in an earlier KEI blog, in January 2010, 361 individuals were on ADAP waitlists; that number grew to 7,873 across eleven states as of May 5, 2011 (a 2100% increase over less than sixteen months).

Continue Reading →

In the first seven months of 2011 (January 14 to July 20) , the US FDA has already approved 18 new molecular entity drugs. These are some notes on the approvals:

• All of the NME products are considered pharmaceutical drugs, and received approval under FDA procedures for New Drug Applications (NDA).
• Despite the trends indiciating shifts to biologic products from pharmaceutical drugs, none of the 2011 products introduced to date were biologics.
• One third (6 of 18) received Priority review status. 12 of 18 received Standard review status.

Continue Reading →

It has been estimated that 1 out of every 8 women in the United States will develop invasive breast cancer during her lifetime. Although a diagnostic test exists to identify mutations on the BRCA1 and BRCA2 human genes, two genes associated with breast and ovarian cancer, many women are not afforded the opportunity to have testing done because Myriad Genetics holds exclusive rights over these genes. Continue Reading →

The WIPO General Assembly meets from Monday, 26 September 2011 to Wednesday, 5 October 2011 and will take place at the International Conference Center Geneva (CICG), 17 rue de Varembé, 1211, Geneva.

The tentative schedule for 49th session of the WIPO General Assembly can be found here: http://www.wipo.int/edocs/mdocs/govbody/en/a_49/a_49_1_prov_2.pdf.

Continue Reading →